Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Topical CBD's Effects on Soreness and Performance

NCT06320327 · View on ClinicalTrials.gov ↗

Study Summary

Exercise-induced muscle damage (EIMD) results from unaccustomed exercise and can lead to delayed onset muscle soreness (DOMS). Impairments associated with EIMD and DOMS can result in moderate-to-severe discomfort and hindered performance. Recently, a compound derived from the cannabis plant, cannabidiol (CBD), has been used as a recovery tool for EIMD and DOMS. Despite the rising popularity of CBD products, their effectiveness in mitigating EIMD and DOMS is unknown. Specifically, to the investigators' knowledge, no clinical trials have been completed to assess the effects of topical CBD cream application on soreness, recovery and performance. Therefore, the purpose of the present study was to investigate the effects of CBD cream on DOMS and performance after an intensive lower-body exercise protocol. Specifically, the study's aims were: Aim 1: To assess the effect of topical CBD cream administration on muscle soreness following fatiguing exercise. Hypothesis 1: CBD cream would decrease perceived muscle soreness when compared to a placebo or control (no cream) group. Aim 2: To assess the effect of topical CBD cream administration on muscular performance following fatiguing exercise. Hypothesis 2: Recovery of muscular power would be quicker when CBD cream is applied, compared to a placebo or control (no cream) group. Aim 3: To assess if topical CBD cream has a localized (if any) or systemic effect on muscle soreness. Hypothesis 3: Improvements in muscle soreness would only be observed in localized muscles around where the CBD cream was applied.

Conditions Studied

Interventions

  • OTHER Cannabidiol cream
  • OTHER Placebo cream

Study Locations (2)

Kentucky

  • Seaton Center Building — Lexington
  • Multidisciplinary Science Building — Lexington

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-08-23
Est. Completion 2023-04-30
Phase NA

Sponsor

Joseph Pastina

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06320327

The ClinicalTrials.gov registry entry for NCT06320327 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joseph Pastina, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Muscle Soreness appearing as the primary indexed condition, and to 2 interventions — of which Cannabidiol cream is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06320327 reports 2 study locations spanning 1 distinct geographic area — top geographies include Kentucky. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06320327 about?

NCT06320327 is a clinical study titled "Topical CBD's Effects on Soreness and Performance". Exercise-induced muscle damage (EIMD) results from unaccustomed exercise and can lead to delayed onset muscle soreness (DOMS). Impairments associated with EIMD and DOMS can result in moderate-to-severe discomfort and hindered performance. Recently, a compound derived from the cannabis plant, cannabi...

What is the current status of trial NCT06320327?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2022-08-23. Estimated completion is 2023-04-30.

What conditions does trial NCT06320327 study?

This clinical trial studies the following conditions: Muscle Soreness. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06320327?

The interventions under investigation include: Cannabidiol cream (OTHER), Placebo cream (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06320327?

This trial is sponsored by Joseph Pastina, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06320327 being conducted?

This trial has 2 study locations across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial